OQS
ADCT icon

Occudo Quantitative Strategies’s ADC Therapeutics ADCT Stock Holding History

Occudo Quantitative Strategies’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-61,858
Closed -$238K – 879
2022
Q4 		$238K Buy
+61,858
New +$247K 0.03% 728

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Occudo Quantitative Strategies's ADCT Position: Q1 2023 in Review

Occudo Quantitative Strategies sold out of ADC Therapeutics (ADCT) in Q1 2023, closing a stake of 61,858 shares — an estimated $238K sold.

Occudo Quantitative Strategies first reported a position in ADCT in Q4 2022 and held it in 1 quarter. The position peaked at $238K in Q4 2022. 59 funds tracked by Wall St. Rank hold ADCT as of Q1 2023.

  • Occudo Quantitative Strategies reported no remaining ADC Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 61,858 ADC Therapeutics shares in Q1 2023, an estimated $238K.
  • Occudo Quantitative Strategies first reported a position in ADC Therapeutics in Q4 2022 and held it in 1 quarter.
  • Occudo Quantitative Strategies's ADC Therapeutics position peaked at $238K in Q4 2022.
  • 59 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2023, filed 15 May 2023.